Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: a retrospective study

Table 2 Univariate and multivariate analysis of predictors of incomplete ablation after the first session of caudate lobe ablation

Factors		Univariate	Multivariate
Factors		P value	HR	95%CI	P value
Gender(M/F)		0.686
Age(≤60/>60y)		0.716
Tumor type (naive/recurrent)		0.088	–	–	–
Etiology (Hepatitis/others)		0.508
Type (Naïve/recurrent)		0.563
Surgery history of liver (Y/N)		0.566
Liver cirrhosis (Y/N)		0.382
Antiviral treatment (Y/N)		0.864
ECOG performance status (0/1)		0.811
Child-Pugh (A/B)		0.221
BCLC stage of primary HCC (A/B)		0.231
AFP (≥400/< 400 μg/L)		0.197
PLT (≥100/< 100 × 10⁹/L)		0.374
PT (≤14/> 14 s)		0.221
ALB (≤35/> 35 g/L)		0.354
ALT (≤40/> 40 IU/L)		1.000
TB (≤17.1/> 17.1 mol/L)		0.401
Tumor number (single /multiple)		0.519
Location (Paracaval portion/ Caudate process/ Spiegel’s lobe)		0.807
Tumor size (≤2 cm/> 2 cm)		0.907
Puncture approach (LA/ RA/ combination approach)		0.177
Treatment strategy	RFA/ EA/ RFA-EA	0.055	–	–	–
	EA/RFA or RFA-EA	0.029	5.031	1.299–19.481	0.019
	RFA or EA/RFA-EA	0.721

HBV hepatitis B virus, HCV hepatitis C virus, ECOG East Coast Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PLT platelets, PT prothrombin time, ALB albumin, ALT alanine aminotransferase, TB total bilirubin, LA left lobe approach, RA right intercostal approach, EA ethanol ablation, RFA radiofrequency ablation, RFA-EA combination of RFA and EA

ISSN: 1471-2407